Dermatology and therapy · 2026
Real-World Ritlecitinib Treatment of Severe Alopecia Areata in the United States: Patient Characteristics and Physician Satisfaction According to a Secondary Database Analysis.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Kurosky Samantha K, Cha-Silva Ashley S, Austin Jenny, Mostaghimi Arash, Kindred Chesahna, Gauthier Genevieve, Sadrarhami Mojgan, Anderson Peter, Ungar Benjamin
Аннотация
INTRODUCTION: Ritlecitinib, an oral, selective dual inhibitor of Janus kinase (JAK) 3 and tyrosine kinase expressed in hepatocellular carcinoma (TEC) family kinases, is approved for treating severe alopecia areata (AA) in patients aged ≥ 12 years in the USA. This study describes characteristics, treatment satisfaction, and success among adults initiating ritlecitinib.
METHODS: A sample of US dermatologists treating adults who received ritlecitinib for severe AA were surveyed between November 2023 and June 2024. Demographics, clinical characteristics, treatment history, satisfaction, and health-related quality of life were analyzed overall, among recent initiators, and stratified by treatment duration.
RESULTS: A total of 123 adults were included (mean age 37.1 years; 57% male; 79% white; 88% commercial insurance). Mean disease duration was 2.1 years. At ritlecitinib initiation (n = 93), mean scalp hair loss was 71% and 73% had worsening AA. The proportion of patients with hair regrowth increased with longer treatment duration, 49% among those with < 3 months of treatment (n = 18/37) to 82% with > 6 months (n = 28/34). Physicians reported many recent initiators (n = 26) felt moderate/severe embarrassment (84%), frustration (73%), and anxiety (65%) due to their AA. Among patients with available data (n = 102), ritlecitinib was the first AA treatment for 46%. Treatment goals (n = 123) included reducing hair loss (94%), improving quality-of-life (41%), and achieving long-term control (32%). Reasons for selecting ritlecitinib (n = 113) included its ability to reduce scalp hair loss (38%), cost-benefit ratio (28%), and safety profile (25%). Satisfaction with AA control was 54%, 68%, and 85% after < 3 (n = 20/37), 3-6 (n = 27/40), and > 6 months (n = 29/34), respectively, of ritlecitinib treatment.
CONCLUSIONS: Many patients experienced psychological burden due to their AA around the start of treatment. Ritlecitinib was chosen for its efficacy, safety, and cost-effectiveness. Hair regrowth, disease stability, and treatment satisfaction increased with longer ritlecitinib treatment duration suggesting sustained treatment is important for achieving treatment goals.
METHODS: A sample of US dermatologists treating adults who received ritlecitinib for severe AA were surveyed between November 2023 and June 2024. Demographics, clinical characteristics, treatment history, satisfaction, and health-related quality of life were analyzed overall, among recent initiators, and stratified by treatment duration.
RESULTS: A total of 123 adults were included (mean age 37.1 years; 57% male; 79% white; 88% commercial insurance). Mean disease duration was 2.1 years. At ritlecitinib initiation (n = 93), mean scalp hair loss was 71% and 73% had worsening AA. The proportion of patients with hair regrowth increased with longer treatment duration, 49% among those with < 3 months of treatment (n = 18/37) to 82% with > 6 months (n = 28/34). Physicians reported many recent initiators (n = 26) felt moderate/severe embarrassment (84%), frustration (73%), and anxiety (65%) due to their AA. Among patients with available data (n = 102), ritlecitinib was the first AA treatment for 46%. Treatment goals (n = 123) included reducing hair loss (94%), improving quality-of-life (41%), and achieving long-term control (32%). Reasons for selecting ritlecitinib (n = 113) included its ability to reduce scalp hair loss (38%), cost-benefit ratio (28%), and safety profile (25%). Satisfaction with AA control was 54%, 68%, and 85% after < 3 (n = 20/37), 3-6 (n = 27/40), and > 6 months (n = 29/34), respectively, of ritlecitinib treatment.
CONCLUSIONS: Many patients experienced psychological burden due to their AA around the start of treatment. Ritlecitinib was chosen for its efficacy, safety, and cost-effectiveness. Hair regrowth, disease stability, and treatment satisfaction increased with longer ritlecitinib treatment duration suggesting sustained treatment is important for achieving treatment goals.